Figure 5.
Figure 5. Efficient protein ablation and similar platelet phenotypes in CD148;Gp1ba-Cre mice. (A) Platelet surface receptor expression of CD148 was measured by flow cytometry of the indicated genotypes and shown as MFI, n = 9 mice per genotype. (B) Platelet surface receptor expression of GPVI was measured by flow cytometry and shown as MFI, n = 6 mice per genotype. (C) Mean platelet aggregation and secretion traces in response to the indicated agonists, n = 5 to 6 mice per condition per genotype. (D) Platelet aggregation in response to the indicated agonists shown as area under the curve (AUC). (A-B,D) Asterisks refer to significant difference in CD148fl/fl;Gp1ba-Cre+/KI or CD148fl/fl;Pf4-Cre+/KI mice compared with CD148+/+;Gp1ba-Cre+/KI or CD148+/+;Pf4-Cre+/KI mice, respectively (***P < .001; 1-way ANOVA with Sidak’s test); data represent mean ± SD.

Efficient protein ablation and similar platelet phenotypes in CD148;Gp1ba-Cre mice. (A) Platelet surface receptor expression of CD148 was measured by flow cytometry of the indicated genotypes and shown as MFI, n = 9 mice per genotype. (B) Platelet surface receptor expression of GPVI was measured by flow cytometry and shown as MFI, n = 6 mice per genotype. (C) Mean platelet aggregation and secretion traces in response to the indicated agonists, n = 5 to 6 mice per condition per genotype. (D) Platelet aggregation in response to the indicated agonists shown as area under the curve (AUC). (A-B,D) Asterisks refer to significant difference in CD148fl/fl;Gp1ba-Cre+/KI or CD148fl/fl;Pf4-Cre+/KI mice compared with CD148+/+;Gp1ba-Cre+/KI or CD148+/+;Pf4-Cre+/KI mice, respectively (***P < .001; 1-way ANOVA with Sidak’s test); data represent mean ± SD.

Close Modal

or Create an Account

Close Modal
Close Modal